Corinne Jenkins
Stock Analyst at Goldman Sachs
(2.45)
# 3,206
Out of 5,182 analysts
59
Total ratings
45.65%
Success rate
2.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Maintains: Neutral | $31 → $35 | $29.04 | +20.52% | 7 | Apr 14, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $24 → $33 | $27.77 | +18.83% | 7 | Dec 15, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $141 → $157 | $84.18 | +86.51% | 11 | Dec 12, 2025 | |
| GERN Geron | Reinstates: Sell | $1 | $1.51 | -33.77% | 4 | Jul 10, 2025 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $34.58 | -36.38% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $7.44 | +101.61% | 2 | May 14, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $2.74 | +374.45% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $31.16 | -10.14% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $1.06 | +5,937.74% | 6 | Aug 15, 2023 | |
| ACRS Aclaris Therapeutics | Maintains: Buy | $25 → $21 | $4.22 | +397.63% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $52.94 | -73.55% | 2 | Dec 20, 2022 |
IDEAYA Biosciences
Apr 14, 2026
Maintains: Neutral
Price Target: $31 → $35
Current: $29.04
Upside: +20.52%
Roivant Sciences
Dec 15, 2025
Maintains: Buy
Price Target: $24 → $33
Current: $27.77
Upside: +18.83%
Rhythm Pharmaceuticals
Dec 12, 2025
Maintains: Buy
Price Target: $141 → $157
Current: $84.18
Upside: +86.51%
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.51
Upside: -33.77%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $34.58
Upside: -36.38%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $7.44
Upside: +101.61%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $2.74
Upside: +374.45%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $31.16
Upside: -10.14%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $1.06
Upside: +5,937.74%
Aclaris Therapeutics
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $4.22
Upside: +397.63%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $52.94
Upside: -73.55%